1167574-41-5

MK-0249 is a histamine H3 inverse antagonist. Current antipsychotic treatments have little impact on the cognitive deficits associated with schizophrenia. It has been proposed that agents which promote histamine release may enhance cognition and, therefore, the H3 inverse agonist MK-0249 might improve cognitive deficits in patients with schizophrenia.